RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--PhytoPharmacon LLC (formerly SaviPu Pharmaceuticals), a privately owned biopharmaceutical company, announced today the issuance of a new patent. The issued patent covers Myriceric acid derivatives for the treatment of cancer, cardiovascular and inflammatory diseases. The company is currently developing a Myriceric Acid A analog for the treatment of Androgen Refractory Prostate Cancer, one of the therapeutic areas of focus for PhytoPharmacon.
